PAGE 111 * RCVD AT 12/12/01 11:33:21 AM [Eastern Standard Time] * SVR:W-PTOFAX-00161 * DNIS:2732885 * CSID: * DURATION (mm-ss):0043 Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (571)-273-2885 INSTRUCTIONS: This farm should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for CURRENT CORRESPONDENCE ADDRESS (Note: Use Block I für eny change of 444rcs) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Bach additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 28171 7590 09/08/2011 DEC 0 1 2011 ENZO BIOCHEM, INC. Certificate of Mailing or Transmission Thereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with inflicient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. 527 MADISON AVENUE (9TH FLOOR). NEW YORK, NY 10022 12/01/2011 CCHAU2 00000073 051135 ELIE GENDLOFF, ESQ. 08486069 (Depositor's pame) (Signature 1740.00 DA 01 FC:1501 02 FC:8001 15.00 DA (Dotc APPLICATION NO. PILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 08/486,069 06/07/1995 ELAZAR RABBANI ENZ-5(D8)(C2) TITLE OF INVENTION: NUCLEIC ACID SEQUENCING PROCESSES USING MODIFIED NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND OTHER PROCESSES FOR NUCLEIC ACID DETECTION AND CHROMOSOMAL CHARACTERIZATION USING SUCH MODIFIED NUCLEOTIDES OR NUCLEOTIDE ANALOGS APPLN. TYPE SMALL ENTITY ISSUE PEE DUE PURLICATION FEE DUE | PREV. PAID ISSUE FEE TOTAL FEE(S) DUB DATE DUE nonprovisional NO \$: 1740 \$ 0 12/08/2011 \$ 1740 **EXAMINER ART UNIT** CLASS-SUBCLASS BRUSCA, JOHN S 1631 435-006000 Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, ! Natalie Bogdanos, Esq. ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed, <u> 2 Elie Gendloff, Esq.</u> © "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev.03-02 or more recent) attached. Use of a Customer Number is required. CUSTOMER NUMBER 28171 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Enzo Biochem, Inc. Farmingdale, NY USA Please check the appropriate assignee category or categories (will not be printed on the patent): 🔲 Individual 🔣 Corporation or other private group cutity 🔲 Government 4a. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) 🖾 Issue Fee A check is enclosed. ☐ Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Otder - # of Copies _____5 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit, Account Number 05-11.35 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27 L b. Applicant is no longer claiming SMALL ENTITY status. See 37 CPR 1.27(8)(2). NOTE: The Issus Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent, or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature . Date <u>December 1, 2013</u> Typed or printed name ELIE GENDLOFF, ESQ. 44704 Registration No. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete from and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTOL-85 (Rev. 02/11) Approved for use through 08/31/2013.

OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE DEC-01-5011 11:33 L.OW:ENZO BIOCHEW